The Barcelona teamβeta Brain Research Centre (BBRC) will present four investigations at the 16th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022). The congress, which will take place from March 15 to 20 in Barcelona and also in hybrid format, on-line, is one of the main scientific meetings for discussion on the mechanisms and treatment of Alzheimer's, Parkinson's and other neurodegenerative diseases. This edition will host three symposia and a poster of some of the BBRC's latest findings:
- Laura Stankeviciute, predoctoral researcher in the Neuroimaging Research Group, will present 'Associations between iron deposition in the brain and AD-like neuroimaging phenotypes in cognitively impaired adults' within the framework of the session AD, PD, LBD: Machine learning, deep learning, EEG, diagnosis. & clinical trials, held on Friday 18th.
- Mahnaz Shekari, predoctoral researcher in the Neuroimaging Research Group, will give the talk 'Evaluating sensitivity of cenriloid quantification to pipeline design' within the symposium AD, FTD, LBD diagnosis. EEG & clinical trials & advances and drug development on Saturday the 19th.
- Dr. Marta del Campo, Head of Fluid Biomarkers Facility, will moderate the symposium Fluid Biomarkers 2, where he will also present the talk 'CFS proteome profiling reveals novel biomarkers for specific diagnosis of dementia with lewy bodies' on Friday 18th.
- Dr. Gemma Salvadó will present the poster 'Increased plasma GFAP is associated with higher cerebral glucose consumption early in the Alzheimer's continuum', which will be on display throughout the conference.
For the first time, this year AD/PD also brings together the Advances in Alzheimer's Therapies Focus Meeting (AAT-AD/PD) conference. The aim of the conference is to provide a space for medical and scientific professionals to discuss the latest advances in treatment, translational research, early diagnosis, drug development and clinical trials of neurodegenerative diseases. Finally, AD/PD aims to foster the emergence of collaborations between academia and industry that contribute to improving the lives of patients and families affected by neurodegenerative diseases.
The full conference program is available here link.
